Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Verimatrix Threat Defense Empowers Capri Healthcare to Safely Digitize Doctor-Patient Care: https://mms.businesswire.com/media/20200603005395/en/795668/5/VMX+logo+4210606c.jpg
Verimatrix Threat Defense Empowers Capri Healthcare to Safely Digitize Doctor-Patient Care


Regulatory News:



Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Capri Healthcare chose Verimatrix App

 NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
 NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results


Regulatory News:



NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

Valbiotis präsentiert positive Ergebnisse seiner klinischen Studie zur Bioverfügbarkeit und Wirkungsweise von TOTUM•070 gegen Hypercholesterinämie: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis präsentiert positive Ergebnisse seiner klinischen Studie zur Bioverfügbarkeit und Wirkungsweise von TOTUM•070 gegen Hypercholesterinämie


Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, qualifiziert für PEA/SME), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease


Regulatory News:



ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for

Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia


Regulatory News:



Valbiotis (FR0013254851 - ALVAL, PEA-SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and

Indischer MSO GTPL Hathway wählt Verimatrix zum Schutz seiner umfangreichen Einführung von Android TV: https://mms.businesswire.com/media/20200603005395/en/795668/5/VMX+logo+4210606c.jpg
Indischer MSO GTPL Hathway wählt Verimatrix zum Schutz seiner umfangreichen Einführung von Android TV


Verimatrix, (Euronext Paris: VMX) (Paris:VMX), der führende Anbieter von kundenorientierten Sicherheitslösungen für die moderne vernetzte Welt, teilte heute mit, dass GTPL Hathway Limited („GTPL“)

Median Technologies Brings Forward Its 2021 Annual Results Publication to April 21, 2022: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg
Median Technologies Brings Forward Its 2021 Annual Results Publication to April 21, 2022


Regulatory News:



Median Technologies (ALMDT:PA) (Paris:ALMDT) announces today that the company will publish its 2021 annual results on April 21, 2022 after trading. The 2021 annual results

Sensorion Will Present at The H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on March 30th, 2022: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Will Present at The H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference on March 30th, 2022


Regulatory News:



Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects: https://mms.businesswire.com/media/20210302005302/en/862456/5/ABIONYX_W.jpg
ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects


Regulatory News:



ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies for

India's GTPL Hathway Selects Verimatrix To Secure Sweeping Android TV Rollout: https://mms.businesswire.com/media/20200603005395/en/795668/5/VMX+logo+4210606c.jpg
India's GTPL Hathway Selects Verimatrix To Secure Sweeping Android TV Rollout


Regulatory News:



Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that GTPL Hathway Limited

Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Provides Preliminary Documents for the Extraordinary General Meeting of April 14th, 2022


Regulatory News:



Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update


POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including

Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance: https://mms.businesswire.com/media/20200113005579/en/767035/5/Median_strapline.jpg
Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance


Regulatory News:



Median Technologies (ALMDT:PA) announces outstanding performance of its iBiopsy LCS AI/ML tech-based end-to-end CADe/CADx Software as Medical Device, intended to enable early

Valbiotis verstärkt sein CSR-Engagement durch den Beitritt zum United Nations Global Compact und die Anwendung der Norm ISO 26000: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis verstärkt sein CSR-Engagement durch den Beitritt zum United Nations Global Compact und die Anwendung der Norm ISO 26000


Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von

Eutelsat and OneWeb Sign Global Distribution Partnership to Address Key Connectivity Verticals: https://mms.businesswire.com/media/20191112005524/en/397236/5/Eutelsat_Communications_logo.jpg
Eutelsat and OneWeb Sign Global Distribution Partnership to Address Key Connectivity Verticals


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005723/en/



Eutelsat Communications (Euronext Paris: ETL) and

Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard


Regulatory News:



Valbiotis (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating

Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

Von Verimatrix in Auftrag gegebene Umfrage zeigt das Ausmaß an Betrügereien, Hacking und Piraterie im E-Sport: https://mms.businesswire.com/media/20200603005395/en/795668/5/VMX+logo+4210606c.jpg
Von Verimatrix in Auftrag gegebene Umfrage zeigt das Ausmaß an Betrügereien, Hacking und Piraterie im E-Sport


Verimatrix, (Euronext Paris: VMX), der führende Anbieter von benutzerorientierten Sicherheitslösungen für die moderne vernetzte Welt, gab heute die Veröffentlichung einer eigens in Auftrag

Verimatrix-Commissioned Survey Highlights Scale of E-Sports Cheating, Hacking and Piracy: https://mms.businesswire.com/media/20200603005395/en/795668/5/VMX+logo+4210606c.jpg
Verimatrix-Commissioned Survey Highlights Scale of E-Sports Cheating, Hacking and Piracy


Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced the release of its commissioned survey conducted by Omdia and the

Sensorion Update on SENS-401: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Update on SENS-401


Regulatory News:



Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and

NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022


NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’)  (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment

GAUSSIN Presents World's First Hydrogen-Powered Fuel Cell Automated Guided Vehicles (AGV H2) for Ports Application
GAUSSIN Presents World's First Hydrogen-Powered Fuel Cell Automated Guided Vehicles (AGV H2) for Ports Application


GAUSSIN (EURONEXT GROWTH ALGAU - FR0013495298), a pioneer in the clean and intelligent transport of goods and people, announces the launch of the world's first hydrogen-powered fuel cell Automated

Valbiotis veröffentlicht Geschäftsbericht für 2021: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis veröffentlicht Geschäftsbericht für 2021


Pflichtmitteilung:



Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und

Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022


Regulatory News:



Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial

Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022: https://mms.businesswire.com/media/20210929005940/en/578635/5/POXEL_LOGO_Q.jpg
Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022


POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including